San Francisco British Consul-General welcomes nanotech
firm to Bay Area
February 25, 2006
SAN FRANCISCO & MOUNTAIN VIEW, Calif.--(BUSINESS
WIRE)--In celebration of the UK-based Oxonica plc's (AIM:OXN)
acquisition of Silicon Valley nanotechnology company, Nanoplex
Technologies, the British Consul-General of San Francisco hosted
a welcome reception Thursday night at the official residence.
The reception drew leading personalities from the
US and UK technology, business, science, finance, and media communities.
Earlier in the day, Oxonica showcased the first of its near-market
ready diagnostic products, advanced nanotechnology-enabled nanotags
with particular capabilities for lateral flow immunoassays, the
format routinely used for home pregnancy tests, infectious disease
diagnosis, biothreat agents and drug abuse detection.
In his welcoming remarks, Martin Uden, British Consul-General,
San Francisco, said, "The US and UK have long had important
ties in science and technology, and it is exciting to see this
continuing into the area of nanotechnology. With its best-of-breed
products already available in Europe and Asia, Oxonica has established
itself as a global presence, perhaps the first truly global nanotechnology
company, and certainly the pre-eminent nanotechnology company
in the UK. In coming to Silicon Valley, Kevin Matthews, David
Browning and the rest of the Oxonica team have proved themselves
to be visionary business leaders. I welcome Oxonica, and look
forward to working with them to grow their business opportunity."
"We thank UK Trade & Investment and the
British Consulate for this wonderful welcome, and are excited
to be in the Bay Area," said Kevin Matthews, CEO of Oxonica
"By acquiring Nanoplex Technologies, we have
established a major business and technology foothold in the US,
and positioned the company to rapidly enter the clinical diagnostics
market. Our goal is to be the global leader in healthcare technologies
enabled by nanomaterials, and the Nanoplex acquisition is a significant
step towards that goal."
"Joining a UK-based company has created a special
opportunity for Nanoplex's technologies," said Michael Natan,
formerly founder of Nanoplex and now president of Oxonica Inc.
"An established and successful infrastructure
for the development and commercialization of nanomaterial-based
products will be vital to the success of Oxonica Inc.'s healthcare
business. The support that the British Consulate has shown, both
for this acquisition and for our business going forward, has been
Oxonica Inc. was formed by Oxonica plc's acquisition
of Nanoplex Technologies in February 2006. When the acquisition
closed earlier this month, Nanoplex was merged with Oxonica Healthcare
and renamed Oxonica Inc. with Michael Natan as president.